Abstract

Influenza virus surface glycoproteins represent the main targets of the immune system during infection and vaccination. Current influenza virus vaccines rely mostly on the hemagglutinin, requiring a close match between the vaccine and circulating strains. Recently, the neuraminidase (NA) has become an attractive target; however low immunogenicity and stability in vaccine preparations remain an obstacles. Here, we took advantage of the hypervariable stalk domain of the NA to introduce cysteines at different positions and to produce more stable multimeric forms of the protein. We generated 11 N1 constructs and characterized the proteins by performing sodium dodecyl sulfate polyacrylamide gel electrophoresis and by testing their enzymatic activity and representation of antigenic epitopes. Moreover, we evaluated their potential to induce a protective immune response in vivo and characterized the polyclonal antibody responses of immunized mice. We observed that the introduction of cysteines at certain positions led to the formation of stable N1 dimers, which are capable of inducing a strong antibody response characterized by neuraminidase inhibiting activity and protection of mice from high dose viral challenge. Overall, our results provide evidence for the feasibility of introducing stalk modifications to enhance the stability and immunogenicity of NA-based recombinant antigens.

Highlights

  • IntroductionIntroduction of Cysteines in the StalkDomain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in MiceShirin Strohmeier 1,2, Juan Manuel Carreño 1 , Ruhi Nichalle Brito 1 and Florian Krammer 1,*

  • Introduction of Cysteines in the StalkDomain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in MiceShirin Strohmeier 1,2, Juan Manuel Carreño 1, Ruhi Nichalle Brito 1 and Florian Krammer 1,*Citation: Strohmeier, S.; Carreño, J.M.; Brito, R.N.; Krammer, F

  • We designed 11 different constructs: AA82-388, containing only the globular head domain of the NA and a 10 amino acid stalk overhang; AA46-388, consisting of the wild type N1 with the full-length stalk domain (62aa); AA46388 (C49A), as a monomer control in which the cysteine at position 49—which is essential for formation of stable dimers—was mutated to alanine [31]; constructs AA46-388 (T48C), AA46-388 (N50C), AA46-388 (T48C, N50C), AA46-388 (A76C), AA46-388 (Q78C), AA46388 (V81C), and AA46-388 (W61C), containing cysteine mutations at different locations in the stalk domain; AA46-388 (VASP), as a tetramer control containing a full-length stalk domain (62aa), as well as a vasodilator-stimulated phosphoprotein (VASP) tetramerization domain [33]

Read more

Summary

Introduction

Introduction of Cysteines in the StalkDomain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in MiceShirin Strohmeier 1,2, Juan Manuel Carreño 1 , Ruhi Nichalle Brito 1 and Florian Krammer 1,*. Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice. We generated 11 N1 constructs and characterized the proteins by performing sodium dodecyl sulfate polyacrylamide gel electrophoresis and by testing their enzymatic activity and representation of antigenic epitopes. We evaluated their potential to induce a protective immune response in vivo and characterized the polyclonal antibody responses of immunized mice. The genome of the influenza A viruses consists of 8 segments that encode at least 11 structural and non-structural proteins [1,2] These viruses carry two major glycoproteins on their surfaces, the hemagglutinin (HA) and the neuraminidase (NA). These drugs are able to reduce viral shedding and improve influenza symptoms if administered at early stages of the infection [15]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.